BioSpace News Archive

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that members of its management team will host an investor call on Thursday, September 7 at 8:00 a.m. ET to share topline results from the Phase 3 pivotal RESPONSE study of seladelpar in patients with primary biliary cholangitis (PBC).

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, Sept. 13, 2023 at 10:30 a.m. ET.

Align Technology, Inc. introduced a new doctor enabled direct ship to patient feature in its Vivera™ Retainer Subscription platform that allows doctors to have subsequent retainers sent directly to their patients in order to meet their ongoing long-term retention needs.

Align Technology, Inc. introduced new software innovations to accelerate digital practice transformation.

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.

New research in the September 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network reveals an alarming lack of access for non-English speakers who called hospitals across the United States looking for information on cancer care services.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 90,000 shares of its common stock to two employees outside Fusion’s 2020 Stock Option and Incentive Plan.

Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET.

Levee Medical, a clinical-stage medical device company designing solutions to improve surgical outcomes following prostate cancer, announced it has raised a total of $4.3 million in oversubscribed funds.

Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.